Agios Pharmaceuticals, Inc

Aviceda Therapeutics, based in Cambridge, MA, focuses on harnessing the body's natural immune system to modulate inflammation. The company utilizes highly selective ligands designed for maximum specificity towards targeted immune cells and diseases. By employing nature's design, Aviceda Therapeutics aims to develop innovative therapeutic solutions that enhance immune responses. Their approach emphasizes precision in targeting, which is crucial for effectively addressing various health conditions. Generated from the website

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.

Lyndra Therapeutics, Inc., based in Watertown, MA, is pioneering long-acting oral therapies aimed at transforming the patient experience by reducing the burden of daily medication regimens. Their innovative LYNX drug delivery platform has the potential for broad applicability across multiple therapeutic areas, including both approved and developing drugs. Generated from the website